Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 61
- Registration Number
- NCT01134315
- Locations
- 🇺🇸
Site Reference ID/Investigator# 26748, Atlanta, Georgia, United States
🇺🇸Site Reference ID/Investigator# 26769, Boston, Massachusetts, United States
🇺🇸Site Reference ID/Investigator# 26749, Akron, Ohio, United States
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Abbott
- Target Recruit Count
- 216
- Registration Number
- NCT01071070
- Locations
- 🇨🇳
Site Reference ID/Investigator# 35822, Wenzhou, China
🇨🇳Site Reference ID/Investigator# 37722, Qingdao, China
🇨🇳Site Reference ID/Investigator# 23485, Beijing, China
Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)
- Conditions
- Interventions
- First Posted Date
- 2009-11-24
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 47
- Registration Number
- NCT01020487
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 10
- Registration Number
- NCT01012414
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Metabolic Effects of Paricalcitol
- First Posted Date
- 2009-10-28
- Last Posted Date
- 2014-04-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 22
- Registration Number
- NCT01003275
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
- Conditions
- Interventions
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Abbott
- Target Recruit Count
- 47
- Registration Number
- NCT00990704
- Locations
- 🇯🇵
Site Ref # / Investigator 53789, Tokyo, Japan
🇯🇵Site Ref # / Investigator 53793, Toyohashi, Japan
🇯🇵Site Ref # / Investigator 53788, Yachiyo, Japan
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
- Conditions
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2012-06-20
- Lead Sponsor
- Abbott
- Target Recruit Count
- 272
- Registration Number
- NCT00977080
- Locations
- 🇺🇸
Site Reference ID/Investigator# 22781, Tempe, Arizona, United States
🇺🇸Site Reference ID/Investigator# 21144, St. Louis, Missouri, United States
🇺🇸Site Reference ID/Investigator# 22770, Philadelphia, Pennsylvania, United States
Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients
- Conditions
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Salem Veterans Affairs Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT00958451
- Locations
- 🇺🇸
VA Medical Center, Salem, Virginia, United States
Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Amy Barton Pai
- Target Recruit Count
- 41
- Registration Number
- NCT00915876
- Locations
- 🇺🇸
Albany Medical Center South Clinical Campus, Albany, New York, United States
Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
- Conditions
- Interventions
- First Posted Date
- 2009-01-15
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 110
- Registration Number
- NCT00823303
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Northshore University Health System, Evanston, Illinois, United States
🇺🇸Washington University, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.